Literature DB >> 23299719

In vitro studies of lanthanide complexes for the treatment of osteoporosis.

Yasmin Mawani1, Jacqueline F Cawthray, Stanley Chang, Kristina Sachs-Barrable, David M Weekes, Kishor M Wasan, Chris Orvig.   

Abstract

Lanthanide ions, Ln(III), are of interest in the treatment of bone density disorders because they are found to accumulate preferentially in bone (in vivo), have a stimulatory effect on bone formation, and exhibit an inhibitory effect on bone degradation (in vitro), altering the homeostasis of the bone cycle. In an effort to develop an orally active lanthanide drug, a series of 3-hydroxy-4-pyridinone ligands were synthesized and eight of these ligands (H1 = 3-hydroxy-2-methyl-1-(2-hydroxyethyl)-4-pyridinone, H2 = 3-hydroxy-2-methyl-1-(3-hydroxypropyl)-4-pyridinone, H3 = 3-hydroxy-2-methyl-1-(4-hydroxybutyl)-4-pyridinone, H4 = 3-hydroxy-2-methyl-1-(2-hydroxypropyl)-4-pyridinone, H5 = 3-hydroxy-2-methyl-1-(1-hydroxy-3-methylbutan-2-yl)-4-pyridinone, H6 = 3-hydroxy-2-methyl-1-(1-hydroxybutan-2-yl)-4-pyridinone, H7 = 1-carboxymethyl-3-hydroxy-2-methyl-4-pyridinone, H8 = 1-carboxyethyl-3-hydroxy-2-methyl-4-pyridinone) were coordinated to Ln(3+) (Ln = La, Eu, Gd, Lu) forming stable tris-ligand complexes (LnL(3), L = 1(-), 2(-), 3(-), 4(-), 5(-), 6(-), 7(-) and 8(-)). The dissociation (pK(an)) and metal ligand stability constants (log β(n)) of the 3-hydroxy-4-pyridinones with La(3+) and Gd(3+) were determined by potentiometric titrations, which demonstrated that the 3-hydroxy-4-pyridinones form stable tris-ligand complexes with the lanthanide ions. One phosphinate-EDTA derivative (H(5)XT = bis[[bis(carboxymethyl)amino]methyl]phosphinate) was also synthesized and coordinated to Ln(3+) (Ln = La, Eu, Lu), forming the potassium salt of [Ln(XT)](2-). Cytotoxicity assays were carried out in MG-63 cells; all the ligands and metal complexes tested were observed to be non-toxic to this cell line. Studies to investigate the toxicity, cellular uptake and apparent permeability (P(app)) of the lanthanide ions were conducted in Caco-2 cells where it was observed that [La(XT)](2-) had the greatest cell uptake. Binding affinities of free lanthanide ions (Ln = La, Gd and Lu), metal complexes and free 3-hydroxy-4-pyridinones with the bone mineral hydroxyapatite (HAP) are high, as well as moderate to strong for the free ligand with the bone mineral depending on the functional group.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23299719     DOI: 10.1039/c2dt32373g

Source DB:  PubMed          Journal:  Dalton Trans        ISSN: 1477-9226            Impact factor:   4.390


  5 in total

Review 1.  Bone-seeking agents for the treatment of bone disorders.

Authors:  Jacqueline Cawthray; Ellen Wasan; Kishor Wasan
Journal:  Drug Deliv Transl Res       Date:  2017-08       Impact factor: 4.617

2.  H6phospa-trastuzumab: bifunctional methylenephosphonate-based chelator with 89Zr, 111In and 177Lu.

Authors:  Eric W Price; Brian M Zeglis; Jason S Lewis; Michael J Adam; Chris Orvig
Journal:  Dalton Trans       Date:  2014-01-07       Impact factor: 4.390

3.  Safety of bioabsorbable implants in vitro.

Authors:  Mehmet Isyar; Ibrahim Yilmaz; Gurdal Nusran; Olcay Guler; Sercan Yalcin; Mahir Mahirogullari
Journal:  BMC Surg       Date:  2015-12-12       Impact factor: 2.102

4.  In vivo study and thermodynamic investigation of two lanthanum complexes, La(dpp)3 and La(XT), for the treatment of bone resorption disorders.

Authors:  J F Cawthray; D M Weekes; O Sivak; A L Creagh; F Ibrahim; M Iafrate; C A Haynes; K M Wasan; C Orvig
Journal:  Chem Sci       Date:  2015-08-03       Impact factor: 9.825

5.  Evaluation of La(XT), a novel lanthanide compound, in an OVX rat model of osteoporosis.

Authors:  Yunyun Di; Ellen K Wasan; Jacqueline Cawthray; Jaweria Syeda; Munawar Ali; David M L Cooper; Ahmad Al-Dissi; Nima Ashjaee; Wubin Cheng; James Johnston; David M Weekes; Thomas I Kostelnik; Chris Orvig; Kishor M Wasan
Journal:  Bone Rep       Date:  2021-02-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.